Clinical Trials Logo

Pituitary Diseases clinical trials

View clinical trials related to Pituitary Diseases.

Filter by:

NCT ID: NCT04938401 Not yet recruiting - Pituitary Tumor Clinical Trials

Construction and Application of a Risk Prediction Model Forepistaxis After Pituitary Tumor Resection

Start date: July 2, 2021
Phase:
Study type: Observational [Patient Registry]

(1) Objective to establish an evaluation system for predicting the risk of epistaxis after endoscopic transsphenoidal pituitary surgery( 2) Objective to determine the risk factors of epistaxis after endoscopic transsphenoidal pituitary adenoma surgery. Referring to domestic and foreign literature, combined with experts' opinions, the related risk factors that may cause postoperative nosebleed of pituitary adenoma are: 22 patients and surgical factors. 3) Objective to establish a risk prediction model of epistaxis after endoscopic transsphenoidal pituitary tumor resection. According to the occurrence of epistaxis, the patients in the modeling group were divided into epistaxis group and non epistaxis group. The risk factors of epistaxis were taken as the independent variable, and the occurrence of epistaxis was taken as the dependent variable. The variables with statistical significance in univariate analysis were included in the multivariate logistic regression model, and the risk prediction model of epistaxis after pituitary tumor resection was established by back LR method.(4) Objective to verify the risk prediction model of endoscopic transsphenoidal pituitary adenoma epistaxis. The validation model is used to validate the prediction model, and the Hosmer-Lemeshow degree is used to match the model. The area under the receiver operating characteristic curve (ROC) was used to evaluate the validity of the model.(5) Application of risk prediction model.

NCT ID: NCT04902235 Completed - Social Isolation Clinical Trials

Identification and Clinical Relevance of an Oxytocin Deficient State (CRH Study)

Start date: July 6, 2021
Phase: Phase 4
Study type: Interventional

Oxytocin (OT) is a hypothalamic peptide that enters the peripheral circulation via the posterior pituitary gland. OT plays a key role in regulating appetite, psychopathology, prosocial behavior and sexual function. Hypopituitarism is associated with increased obesity, increased psychopathology, sexual and prosocial dysfunction despite appropriate hormone replacement. A few studies suggest the existence of a possible OT deficient state in hypopituitarism. In animal models, corticorelin hormone (CRH) has shown to increase OT release. This study is designed to evaluate oxytocin values after administration of CRH in adults (healthy volunteers and patients with hypopituitarism). The investigators hypothesize that OT response will be blunted following CRH in patients with hypopituitarism compared to healthy controls.

NCT ID: NCT04897802 Recruiting - Social Isolation Clinical Trials

Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)

Start date: September 13, 2021
Phase: Phase 4
Study type: Interventional

Oxytocin (OT) is a hypothalamic peptide that enters the peripheral circulation via the posterior pituitary gland. OT plays a key role in regulating appetite, psychopathology, prosocial behavior and sexual function. Hypopituitarism is associated with increased obesity, increased psychopathology, sexual and prosocial dysfunction despite appropriate hormone replacement. A few studies suggest the existence of a possible OT deficient state in hypopituitarism. In animal models, glucagon-like peptide 1 (GLP1) has shown to increase OT release. This study is designed to evaluate OT values after administration of GLP1 in adults (healthy volunteers and patients with hypopituitarism). The investigators hypothesize that OT response will be blunted following GLP1 receptor agonist (GLP1-RA) in patients with hypopituitarism compared to healthy controls.

NCT ID: NCT04865744 Completed - Healthy Clinical Trials

The Effect of Semaglutide on Pituitary Function

Start date: May 19, 2021
Phase: Phase 4
Study type: Interventional

The primary aim of the study is to describe the effect of a single oral dose of semaglutide 7 mg on growth hormone secretion.

NCT ID: NCT04863456 Not yet recruiting - Pituitary Adenoma Clinical Trials

Efficiency and Safety of Different Treatment Strategies in Adults With Pituitary Adenomas With Hypothalamic Involvement

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

Prospective and randomized evaluate efficiency and safety of different treatment strategies for hypothalamus-invading pituitary adenomas (HIPA)

NCT ID: NCT04863339 Withdrawn - Surgery Clinical Trials

Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery

Start date: March 2022
Phase: Phase 2
Study type: Interventional

This trial is to determine the effect of Tranexamic Acid (TXA) on blood loss during endoscopic pituitary surgery. The hypothesis of this study is that TXA will reduce blood loss during surgery compared to a placebo. To answer this hypothesis, the investigators are conducting a randomized controlled trial in which half of participants will receive TXA and half will receive placebo (saline) in a double blind fashion.

NCT ID: NCT04840771 Completed - Pituitary Adenoma Clinical Trials

Predictive OCTA Biomarkers After Endoscopic Endonasal Pituitary Surgery

Start date: June 1, 2020
Phase:
Study type: Observational

This study evaluates the structural parameters, by spectral domain optical coherence tomography (OCT), retinal vessel density, using OCT angiography, and visual acuity in patients that received endoscopic endonasal approach for the removal of an intra-suprasellar pituitary adenoma compressing the optic nerve.

NCT ID: NCT04785222 Not yet recruiting - Clinical trials for Intraoperative Pain Control

Infraorbital Nerve Block for Endoscopic Transsphenoidal Approach to Remove Pituitary Tumor

Start date: July 2021
Phase: Phase 4
Study type: Interventional

Perioperative pain relief during endoscopic transsphenoidal pituitary surgery is generally treated with opioids either morphine sulfate or fentanyl. This study will compare the traditional method of intravenous fentanyl to the bilateral infraorbital nerve block in adult patients scheduled for pituitary surgery by the transsphenoidal approach.

NCT ID: NCT04782596 Completed - Pituitary Adenoma Clinical Trials

Transnasal Endoscopic Pituitary Surgery - the Effect of Posterior Nasal Septum Resection on Nasal Functions

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

The aim of the project is to compare the effect of different extent of resection of the posterior part of the septum on the postoperative nasal functions.

NCT ID: NCT04713293 Recruiting - Pituitary Disease Clinical Trials

China Pituitary Disease Registry (CAPASITY)

Start date: July 26, 2020
Phase:
Study type: Observational

Epidemiologic studies have revealed a tremendous increase in the prevalence of pituitary disease and related mortality worldwide. In order to meet all the challenges in the treatment of pituitary disease in China, CAPASITY was founded in 2020. The objective of CAPASITY is to launch a pituitary disease management model based on the Internet health information platform. It allows the application and evaluation of pituitary disease treatment strategies at multiple centers. The proprietary electronic medical database will help the dynamic big-data analysis in epidemiology of pituitary disease, diagnosis, and treatment.